Quarterly ResultAug 13, 2026, 04:27 PM
Tempest Therapeutics Partners for CAR-T Development; Q2 Net Loss $5.2M
AI Summary
Tempest Therapeutics reported its Q2 2026 financial results, including a net loss of $5.2 million and $0.8 million in cash. The company announced a development collaboration with Senlang Biotechnology for its in vivo CAR-T product candidate, TPST-4003, with first patient dosing expected in Q4 2026. Additionally, positive interim results were reported for TPST-2003, showing a 100% complete response rate in CAR-T-naïve patients. The company also appointed two new independent directors to its Board.
Key Highlights
- Executed a development collaboration with Senlang Biotechnology for in vivo CAR-T product candidates, including TPST-4003.
- First patient dosing for TPST-4003 anticipated in Q4 2026, with initial clinical data expected in H1 2027.
- TPST-2003 reported positive interim results, including a 100% complete response rate in 15 CAR-T-naïve patients.
- Appointed Drake Richey and John Yee, MD, MPH, as independent directors to the Board.
- Reported a Q2 2026 net loss of $5.2 million, compared to $7.9 million for Q2 2025.
- Cash and cash equivalents were $0.8 million as of June 30, 2026, down from $7.7 million on December 31, 2025.
- Research and development expenses for Q2 2026 decreased to $1.8 million from $3.9 million in Q2 2025.
Price Impact
More from TPST